FDA grants Orphan Drug Designation to TK216

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA granted Orphan Drug Designation to TK216 for the treatment of Ewing sarcoma. Oncternal Therapeutics Inc., the drug’s sponsor, is in the process of initiating a first-in-human phase I trial of TK216 in relapsed or refractory Ewing sarcoma. The company recently received Fast Track Designation in this indication. TK216 is a first-in-class small molecule that...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

As NCI and NIH funding is being deliberated in Congress, this year’s 2025 AACR Cancer Progress Report had an unequivocal message: With 20 new anticancer therapeutics, new uses for eight previously approved anticancer therapeutics, two new early detection tools, and several AI-powered diagnostics approved over the span of just one year, cancer research funding yields a good return on investment. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login